Itulazax

News

A once-daily tablet that can help people suffering from hay fever caused by tree pollen, Alk-Abelló's Itulazax, has been recommended for NHS use.

News

Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.